Absci Appoints Ransi Somaratne as CMO; CIO Busch Retires March 31
Absci has named Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer to lead clinical development for its AI-designed pipeline, including flagship ABS-201. Concurrently, Chief Innovation Officer Andreas Busch will retire on March 31, 2026 and transition to co-chair the Scientific Advisory Board.
1. Appointment of Chief Medical Officer
Absci has appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer to spearhead clinical development strategy for its generative AI–designed therapeutics pipeline. He will oversee advancement of multiple programs, including the flagship ABS-201 program toward clinical proof of concept.
2. CIO Andreas Busch Retirement
Chief Innovation Officer Andreas Busch will retire from his executive duties on March 31, 2026 and immediately assume the role of co-chair of Absci’s Scientific Advisory Board. In this advisory capacity he will continue to guide scientific strategy and oversight for the company’s AI-driven discovery efforts.
3. Strategic Impact on AI-Designed Pipeline
Somaratne’s track record at Vertex, BioMarin and Amgen—highlighted by work on Roctavian®, Repatha® and Journavx®—is expected to bolster Absci’s clinical execution capabilities. The leadership transition positions Absci to accelerate its Integrated Drug Creation™ platform and advance its pipeline toward key development milestones.